C
84.95
0.00 (0.00%)
| Previous Close | 84.95 |
| Volume | 8,182,078 |
| Price / Sales | 201.01 |
| Price / Book | 7.56 |
| 52 Weeks Range |
| Operating Margin (TTM) | -30,860.11% |
| Diluted EPS (TTM) | -3.80 |
| Quarterly Revenue Growth (YOY) | -43.60% |
| Total Debt/Equity (MRQ) | 4.05% |
| Current Ratio (MRQ) | 22.53 |
| Operating Cash Flow (TTM) | -261.57 M |
| Levered Free Cash Flow (TTM) | -155.77 M |
| Return on Assets (TTM) | -20.13% |
| Return on Equity (TTM) | -30.84% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Crinetics Pharmaceuticals, Inc. | Mixed | Bullish |
AIStockmoo Score
| Value 35% | 0.0 |
| AI Insight info | NA |
| Relative Valuation info | NA |
| Financial Health info | 0.0 |
| Timing 35% | 0.0 |
| AI Technical info | NA |
| Technical Oscillators info | 0.0 |
| Technical Moving Averages info | 0.0 |
| Smart Money 30% | 0.0 |
| Analyst Consensus info | 0.0 |
| Insider Activity info | NA |
| Environment | ×0.79 |
| Macro Environment info | -3.3 |
| Sector vs Market (6M) | -21.3% |
| Pillar Agreement | ×1.00 |
| Not in score | |
| Price Volatility info | NA |
| Final Score | 0.00 |
Select this tab to load the latest available analysis.
|
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its products include Paltusotine and Atumelnant. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 2.03% |
| % Held by Institutions | 112.39% |
No data within this time range.
No data within this time range.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |